Author

Gabriel Tinoco

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Pimicotinib versus placebo in tenosynovial giant cell tumor (TGCT): a plain language summary of the MANEUVER clinical trial.

What is this summary about?This summary describes the main findings of the MANEUVER clinical trial for pimicotinib, a once-daily treatment. The goal was to see if pimicotinib could significantly reduce tumor size after 24 weeks of treatment in clinical trial participants with tenosynovial giant cell tumor (TGCT) comp...

H. Gelderblom, Xiao-Hui Niu, S. Stacchiotti et al. · Future Oncology · 0 citations

Review Open access Oct 2026

Long-term efficacy, clinical outcomes, and safety of vimseltinib in patients with tenosynovial giant cell tumor: results from the MOTION phase 3 trial

Abstract Background Tenosynovial giant cell tumor (TGCT) is a locally aggressive neoplasm caused by colony-stimulating factor 1 (CSF1) gene dysregulation. Vimseltinib is an oral, switch-control tyrosine kinase inhibitor of the CSF1 receptor. In part 1 of the MOTION phase 3 trial, vimseltinib demonstrated statistically...

V. Bhadri, H. Gelderblom, S. Stacchiotti et al. · The Oncologist · 0 citations

Review Open access Oct 2026

Longitudinal PROMIS10 global health scores as independent prognostic values in advanced sarcoma.

417 Background: Patients with advanced sarcoma experience significant symptom burden from disease and treatment, contributing to emergency department (ED) visits and unplanned hospitalization. There are no US-based studies evaluating longitudinal health-related quality of life (HRQoL) assessments using patient-...

H. Alsharif, Yue Yu, Saurabh D. Chitnis et al. · JCO Oncology Practice · 0 citations